Novo Nordisk tests own mobile app in phase III trial with insulin hope
An internally-developed mobile app from Novo Nordisk will be part of a phase III trial involving the pharmaceutical company's grand hope insulin icodec. This app will help diabetes patients find their optimal insulin doses based on earlier doses and their blood sugar levels.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
Read this article for free
Register with your E-mail. No credit card required.